Markert JM - Search Results

1

Pediatric cancer gone viral. Part I: strategies for utilizing oncolytic herpes simplex virus-1 in children.

Cripe TP, Chen CY, Denton NL, Haworth KB, Hutzen B, Leddon JL, Streby KA, Wang PY, Markert JM, Waters AM, Gillespie GY, Beierle EA, Friedman GK. Cripe TP, et al. Among authors: markert jm. Mol Ther Oncolytics. 2015;2:15015-. doi: 10.1038/mto.2015.15. Epub 2015 Sep 16. Mol Ther Oncolytics. 2015. PMID: 26436135 Free PMC article.

2

The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors.

Andreansky SS, He B, Gillespie GY, Soroceanu L, Markert J, Chou J, Roizman B, Whitley RJ. Andreansky SS, et al. Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11313-8. doi: 10.1073/pnas.93.21.11313. Proc Natl Acad Sci U S A. 1996. PMID: 8876132 Free PMC article. Review.

3

Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors.

Andreansky S, Soroceanu L, Flotte ER, Chou J, Markert JM, Gillespie GY, Roizman B, Whitley RJ. Andreansky S, et al. Among authors: markert jm. Cancer Res. 1997 Apr 15;57(8):1502-9. Cancer Res. 1997. PMID: 9108452

4

Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins.

Andreansky S, He B, van Cott J, McGhee J, Markert JM, Gillespie GY, Roizman B, Whitley RJ. Andreansky S, et al. Among authors: markert jm. Gene Ther. 1998 Jan;5(1):121-30. doi: 10.1038/sj.gt.3300550. Gene Ther. 1998. PMID: 9536273

5

Replication-competent, nonneuroinvasive genetically engineered herpes virus is highly effective in the treatment of therapy-resistant experimental human tumors.

Advani SJ, Chung SM, Yan SY, Gillespie GY, Markert JM, Whitley RJ, Roizman B, Weichselbaum RR. Advani SJ, et al. Among authors: markert jm. Cancer Res. 1999 May 1;59(9):2055-8. Cancer Res. 1999. PMID: 10232586

6

Ionizing radiation improves survival in mice bearing intracranial high-grade gliomas injected with genetically modified herpes simplex virus.

Bradley JD, Kataoka Y, Advani S, Chung SM, Arani RB, Gillespie GY, Whitley RJ, Markert JM, Roizman B, Weichselbaum RR. Bradley JD, et al. Among authors: markert jm. Clin Cancer Res. 1999 Jun;5(6):1517-22. Clin Cancer Res. 1999. PMID: 10389941

7

Genetically engineered HSV in the treatment of glioma: a review.

Markert JM, Gillespie GY, Weichselbaum RR, Roizman B, Whitley RJ. Markert JM, et al. Rev Med Virol. 2000 Jan-Feb;10(1):17-30. doi: 10.1002/(sici)1099-1654(200001/02)10:1<17::aid-rmv258>3.0.co;2-g. Rev Med Virol. 2000. PMID: 10654002 Review.

8

Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors.

Parker JN, Gillespie GY, Love CE, Randall S, Whitley RJ, Markert JM. Parker JN, et al. Among authors: markert jm. Proc Natl Acad Sci U S A. 2000 Feb 29;97(5):2208-13. doi: 10.1073/pnas.040557897. Proc Natl Acad Sci U S A. 2000. PMID: 10681459 Free PMC article.

9

Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial.

Markert JM, Medlock MD, Rabkin SD, Gillespie GY, Todo T, Hunter WD, Palmer CA, Feigenbaum F, Tornatore C, Tufaro F, Martuza RL. Markert JM, et al. Gene Ther. 2000 May;7(10):867-74. doi: 10.1038/sj.gt.3301205. Gene Ther. 2000. PMID: 10845725 Clinical Trial.

10

Differential gene expression profiling in human brain tumors.

Markert JM, Fuller CM, Gillespie GY, Bubien JK, McLean LA, Hong RL, Lee K, Gullans SR, Mapstone TB, Benos DJ. Markert JM, et al. Physiol Genomics. 2001 Feb 7;5(1):21-33. doi: 10.1152/physiolgenomics.2001.5.1.21. Physiol Genomics. 2001. PMID: 11161003

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

185 results

Search Page

Filters